Clinical Trials in Jacksonville Florida

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma
NCT03477539
Conditions: Minimal Residual Disease; Plasma Cell Myeloma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation; Biological: Daratumumab; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Other: Pharmacokinetic Study
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
Open-Label Safety Study of AXS-05 in Subjects With Depression
NCT04039022
Conditions: Major Depressive Disorder; Treatment Resistant Depression; Depression
Intervention: Drug: AXS-05
Sponsor: Axsome Therapeutics, Inc.
Recruiting
Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
NCT04028947
Condition: Knee Pain Chronic
Intervention: Procedure: Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
Sponsor: Mayo Clinic
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder
NCT04019704
Conditions: Depression; Major Depressive Disorder
Interventions: Drug: AXS-05; Drug: Placebo
Sponsor: Axsome Therapeutics, Inc.
Recruiting
Early Active Controlled Motion (EACM) Rehabilitation Protocol Post Open Reduction and Internal Fixation (ORIF) of Scaphoid Fractures: A Pilot Study
NCT03996512
Condition: Scaphoid Fixation
Intervention: Other: Early Active Controlled Motion (EACM)
Sponsors: University of Florida; Performance Health
Recruiting
Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
NCT03941483
Condition: Acute Kidney Injury (AKI)
Interventions: Drug: ASP1128; Drug: Placebo
Sponsor: Astellas Pharma Inc
Recruiting
Functional Predictive Value of Collective Outcome Measure(s) Status Post Total Hip/Knee Arthroplasty
NCT03933969
Conditions: Joint Arthroplasty; Knee and Hip
Intervention:
Sponsor: Mayo Clinic
Recruiting
Spanish Translation and Cultural Adaptation of the Memory Support System
NCT03933085
Condition: Mild Cognitive Impairment
Intervention: Behavioral: Memory Support System (MSS)
Sponsor: Mayo Clinic
Recruiting
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
NCT03929120
Conditions: Interstitial Lung Disease; Connective Tissue Diseases
Intervention: Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Sponsor: Mayo Clinic
Recruiting
Initial Assessment of a Topical Cadexomer Iodine Gel Efficacy on Keloid Scar Revision
NCT03876548
Condition: Keloid Scar Following Surgery
Intervention: Device: Cadexomer Iodine Gel
Sponsors: Next Science TM; Jacksonville Center For Clinical Research
Recruiting
Next-Generation Pre-Operative Targeting for Thalamic DBS in the Treatment of Tremor
NCT03875404
Condition: Essential Tremor
Intervention: Diagnostic Test: Functional MRI
Sponsor: Mayo Clinic
Recruiting
fMRI of Active DBS Stimulation in Epilepsy
NCT03870308
Condition: Epilepsy
Intervention: Diagnostic Test: Functional MRI
Sponsor: Mayo Clinic
Recruiting
Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty
NCT03845881
Condition: Total Knee Arthroplasty
Interventions: Drug: Oxycodone; Drug: Placebo Oral Tablet
Sponsors: Mayo Clinic; Ambit Biosciences Corporation; Kern Medical Center
Recruiting
Development of a Risk Prediction Screening Tool for Opioid-Prescription Injury (STOP Injury) in Older Adults Initiated on Opioids From the Emergency Department
NCT03836235
Condition: Opioid Use
Intervention:
Sponsors: University of Florida; National Institute on Aging (NIA); US Department of Health and Human Services
Recruiting
Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic
NCT03828890
Condition: Diabetes Mellitus
Intervention: Diagnostic Test: Screening eye exam using Optos technology
Sponsor: Mayo Clinic
Recruiting
Intravital Microscopy in Human Solid Tumors
NCT03823144
Condition: Solid Tumor, Adult
Intervention: Device: Human Intravital Microscopy
Sponsor: Mayo Clinic
Recruiting
Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates
NCT03811873
Conditions: Metabolic Bone Disease; Transplant-Related Disorder; Secondary Osteoporosis
Intervention: Radiation: Thoracic spine X-Ray
Sponsor: Mayo Clinic
Recruiting
Treating Acute Pancreatitis With Dabigatran, a Pilot Study
NCT03807856
Condition: Acute Pancreatitis
Interventions: Drug: Dabigatran Etexilate Mesylate; Other: Standard of Care
Sponsor: Mayo Clinic
Recruiting
The Distal (SnUffbox) Radial artERy Access for Coronary Angiography and Interventions (SUPER-Prospective)
NCT03794687
Condition: Coronary Angiography
Intervention: Procedure: Left heart catheterization
Sponsor: University of Florida
Recruiting
Stimulation to Enhance Walking Post-SCI
NCT03702842
Conditions: SCI - Spinal Cord Injury; Incomplete Spinal Cord Injury
Interventions: Device: Soterix Medical tsDCS stimulator; Other: Locomotor training
Sponsors: University of Florida; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
NCT03624660
Condition: Adenocarcinoma of the Prostate
Interventions: Radiation: HR-A; Radiation: HR-B; Radiation: HR-C
Sponsor: University of Florida
Recruiting
Awake vs. Asleep Craniotomy for Non-eloquent Gliomas
NCT03621748
Condition: Intracranial Glioma
Interventions: Procedure: Awake Anesthesia Protocol; Procedure: Non-awake Anesthesia Protocol
Sponsor: Mayo Clinic
Recruiting
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH
NCT03611790
Condition: Cerebral Vasospasm
Intervention: Device: NeVa VS
Sponsor: Vesalio
Recruiting
Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.
NCT03564665
Condition: Hot Flashes
Interventions: Dietary Supplement: 400mg Magnesium Glycinate BID; Other: Placebo
Sponsor: Mayo Clinic
Recruiting
Clinical Practice Guidelines for Neck and Low Back Pain in Outpatient Physical Therapy
NCT03523793
Conditions: Neck Pain; Low Back Pain
Interventions: Behavioral: Clinical Practice Guideline Implementation; Other: Standard Care
Sponsors: University of Florida; Center on Health Services Training and Research (CoHSTAR); Brooks Rehabilitation
Recruiting
Critical Care and Palliative Care Medicine Together in the ICU
NCT03520023
Conditions: Palliative Care; Intensive Care Unit; Hospice
Intervention: Other: Palliative Care Consult
Sponsor: Mayo Clinic
Recruiting
Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia
NCT03506373
Conditions: Recurrent Waldenstrom Macroglobulinemia; Refractory Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib; Drug: Ixazomib Citrate; Other: Laboratory Biomarker Analysis; Other: Pharmacodynamic Study; Other: Pharmacokinetic Study
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
Incorporating Multidimensional Psychosocial Interventions Improves the Well-being of Individuals With Epilepsy
NCT03484039
Conditions: Epilepsy; Seizure Disorder
Interventions: Behavioral: Medication Adherence; Behavioral: Seizure Documentation; Behavioral: Memory Improvement; Behavioral: Stress Management
Sponsors: University of Florida; Dupont Fund, Jesse Ball; Florida Blue Foundation; Riverside Hospital Foundation
Recruiting
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
NCT03437044
Conditions: Diabetes Mellitus, Type 2; Coronary Artery Disease
Interventions: Drug: Ticagrelor; Drug: Clopidogrel
Sponsors: University of Florida; AstraZeneca
Recruiting
Effects of Fermented Vegetables on Gut Microflora and Inflammation in Women
NCT03407794
Conditions: Inflammation; Overweight and Obesity; Gastrointestinal Microbiome
Interventions: Other: Fermented vegetable; Other: Non-fermented vegetable
Sponsors: University of North Florida; University of Arkansas
Recruiting
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
NCT03404661
Condition: Pancreatic Cancer
Intervention: Drug: Synthetic Human Secretin
Sponsor: Mayo Clinic
Recruiting
Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage
NCT03371329
Conditions: Hemorrhagic Stroke; Intracerebral Hemorrhage
Intervention: Biological: MSC
Sponsor: Mayo Clinic
Recruiting
Engineering Gut Microbiome to Target Breast Cancer
NCT03358511
Condition: Breast Cancer
Intervention: Dietary Supplement: Probiotic
Sponsor: Mayo Clinic
Recruiting
Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids
NCT03317795
Conditions: Heavy Menstrual Bleeding; Menorrhagia; Uterine Fibroids
Interventions: Drug: Levonorgestrel IUS; Drug: Tranexamic Acid
Sponsors: Shannon K. Laughlin-Tommaso; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
Microfidelity (MIFI) Ablation Technology Versus Standard Ablation Catheter for Atrioventricular Nodal Ablation
NCT03114124
Condition: Atrial Fibrillation
Interventions: Device: MIFI Catheter; Device: Standard Ablation Catheter
Sponsor: University of Florida
Recruiting
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
NCT03096288
Condition: Atherosclerotic Cardiovascular Disease
Interventions: Drug: Evolocumab; Other: Placebo
Sponsors: University of Florida; Amgen
Recruiting
Vacuum-Assisted Dressings (V-AD) in the Management of Open Chest Wounds
NCT02803164
Condition: Open Chest Wounds
Intervention: Device: Wound Vacuum-assisted dressing
Sponsor: Mayo Clinic
Recruiting
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT02598349
Condition: Pancreatic Cancer
Interventions: Radiation: Proton Radiation; Drug: Capecitabine; Procedure: Surgical resection; Behavioral: FACT-Hep questionnaire
Sponsors: Proton Collaborative Group; University of Florida Health
Recruiting
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
NCT02539160
Conditions: Coronary Artery Disease; Diabetes Mellitus
Intervention: Drug: ticagrelor
Sponsor: University of Florida
Recruiting
Acupuncture Relief for Chronic Neck Pain
NCT03859011
Condition: Neck Pain, Posterior
Interventions: Other: Acupuncture; Other: Usual Care
Sponsors: University of Florida; Utica College
Recruiting
Study of Cardiac MRI in Patients With Left-Sided Breast Cancer Receiving Radiation Therapy
NCT02199366
Condition: Breast Cancer
Intervention: Procedure: Cardiac magnetic resonance (cardiac MRI)
Sponsors: University of Florida; Ocala Royal Dames
Recruiting
Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy
NCT02069847
Condition: Esophageal Stricture
Intervention: Drug: Budesonide
Sponsor: Mayo Clinic
Recruiting
Biomarkers in Aortic Stenosis - B.A.S.S.
NCT01334801
Conditions: Aortic Stenosis; Disorder of Prosthetic Cardiac Valve; Aortic Valve Insufficiency; Mitral Valve Insufficiency; Hypertrophic Cardiomyopathy; Tricuspid Valve Insufficiency
Intervention: Procedure: Blood Draw
Sponsor: Mayo Clinic
Recruiting
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT00969111
Condition: Prostate Cancer
Interventions: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE; Radiation: Proton (prostate bed) to 70.2 CGE; Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE; Radiation: Proton to 66.6 CGE
Sponsors: Proton Collaborative Group; University of Florida Health
Recruiting
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
NCT03865212
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Metastatic Uveal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Unresectable Melanoma
Intervention: Drug: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS
NCT03793829
Condition: DCIS
Intervention: Biological: (H2NVAC)
Sponsor: Mayo Clinic
Recruiting
EmboTrap® Revascularization Device Post Market Registry
NCT03685578
Condition: Cerebral Stroke
Intervention: Device: EmboTrap® Revascularization Device
Sponsor: Neuravi Limited
Recruiting
Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim
NCT03440047
Condition: Gastro-Intestinal Disorder
Intervention: Device: Fuji Flim Processor VP-7000, Light Source BL-7000
Sponsors: Mayo Clinic; Fujifilm Medical Systems USA, Inc.
Recruiting
Shared Decision Making in Patients With Thyroid Nodules
NCT02878044
Conditions: Thyroid Nodule; Thyroid Cancer
Intervention: Other: Thyroid Decision Aid
Sponsor: Mayo Clinic
Recruiting
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
NCT03342573
Condition: PITYRIASIS RUBRA PILARIS
Intervention: Drug: Cosentyx
Sponsor: Mayo Clinic
Recruiting
Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury
NCT03071393
Condition: Spinal Cord Injuries
Intervention: Device: Hypoxico Hyp-123
Sponsor: University of Florida
Recruiting
Breast Cancer Lung Late Effects
NCT02725840
Conditions: Radiation Injury; Breast Cancer
Interventions: Radiation: Proton beam radiation therapy.; Radiation: X-ray based radiation therapy; Procedure: Computed Tomography (CT) Scan; Procedure: Pulmonary Function Test (PFT)
Sponsors: University of Florida; Florida Department of Health
Recruiting
Diaphragm Pacing After Spinal Cord Injury
NCT02556125
Condition: Injuries, Spinal Cord
Intervention: Device: Diaphragm pacing
Sponsors: University of Florida; Brooks Rehabilitation; The Craig H. Neilsen Foundation
Recruiting
LIPIDS-P Trial Phase I/II
NCT03405870
Conditions: Sepsis, Severe; Septic Shock
Intervention: Drug: Smoflipid
Sponsors: University of Florida; Fresenius Kabi
Recruiting
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
NCT03960177
Condition: Osteosarcoma
Intervention: Drug: Glucarpidase
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting
The TOGETHER Project - Liver
NCT03874286
Condition: Liver Transplant Rejection
Intervention: Diagnostic Test: Liver Transplant
Sponsor: Mayo Clinic
Recruiting
The TOGETHER Project - Kidney
NCT03873623
Condition: Kidney Transplant Rejection
Intervention:
Sponsor: Mayo Clinic
Recruiting
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
NCT03281902
Conditions: Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
NCT03242824
Condition: Glioma
Interventions: Drug: Fluorine F 18 Fluorodopa; Radiation: Intensity-Modulated Radiation Therapy; Procedure: Positron Emission Tomography
Sponsor: Mayo Clinic
Recruiting
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
NCT03237390
Conditions: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
Interventions: Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Ribociclib
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02312245
Conditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Bevacizumab; Drug: Gemcitabine Hydrochloride; Drug: Paclitaxel; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Drug: Topotecan Hydrochloride
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
NCT01415882
Conditions: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
Interventions: Drug: Cyclophosphamide; Drug: Dexamethasone; Drug: Ixazomib Citrate; Other: Laboratory Biomarker Analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI); Janssen Scientific Affairs, LLC
Recruiting
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358
Condition: Lymphoma
Interventions: Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: lenalidomide; Drug: prednisone; Drug: vincristine sulfate; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
NCT01871766
Condition: Rhabdomyosarcoma
Interventions: Drug: Vincristine; Drug: Dactinomycin; Drug: Cyclophosphamide; Procedure: Surgical Resection; Procedure: Radiation; Drug: Bevacizumab; Drug: Sorafenib; Drug: Myeloid Growth Factor; Procedure: Lymph Node Sampling; Drug: Irinotecan; Drug: Ifosfamide; Drug: Etoposide; Drug: Etoposide Phosphate; Drug: Doxorubicin; Drug: Dexrazoxane; Drug: ^1^1C-methionine
Sponsor: St. Jude Children's Research Hospital
Recruiting
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
NCT02772003
Conditions: Chronic Hepatitis; Hepatitis C Infection
Interventions: Biological: DNA Plasmid Encoding Interleukin-12 INO-9012; Biological: Electroporation-Mediated Plasmid DNA Vaccine Therapy; Biological: HCV DNA Vaccine INO-8000; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: National Cancer Institute (NCI); Inovio Pharmaceuticals
Recruiting
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma
NCT03418038
Conditions: High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Lymphoma
Interventions: Dietary Supplement: Ascorbic Acid; Drug: Carboplatin; Drug: Cisplatin; Drug: Cytarabine; Drug: Dexamethasone; Drug: Etoposide; Drug: Gemcitabine Hydrochloride; Drug: Ifosfamide; Other: Laboratory Biomarker Analysis; Drug: Oxaliplatin; Other: Placebo; Other: Questionnaire Administration; Biological: Rituximab
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer
NCT03200704
Conditions: Breast Cancer; Lymph Node Mapping; Sentinel Lymph Node Biopsy
Intervention: Combination Product: IC2000 and SPY-PHI
Sponsor: Novadaq Technologies ULC, now a part of Stryker
Recruiting
Vancomycin for Primary Sclerosing Cholangitis
NCT03710122
Condition: Primary Sclerosing Cholangitis
Interventions: Drug: Vancomycin; Other: Placebo
Sponsors: Elizabeth Carey; Arizona State University
Recruiting
A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
NCT03761095
Condition: Leiomyosarcoma
Interventions: Drug: PTC596; Drug: Dacarbazine
Sponsor: PTC Therapeutics
Recruiting
Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy
NCT03459339
Condition: Barrett Esophagus
Intervention: Device: Tethered Capsule Endomicroscopy (TCE)
Sponsors: Massachusetts General Hospital; Columbia University; Mayo Clinic; Kansas City Veteran Affairs Medical Center; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
NCT03420014
Condition: Unresectable or Metastatic Soft Tissue Sarcoma
Interventions: Drug: Doxorubicin; Combination Product: L19TNF plus doxorubicin
Sponsor: Philogen S.p.A.
Recruiting
Integrated Tele-monitoring and Patient-centric Health Coaching Strategy in Patients Hospitalized With Heart Failure
NCT02391987
Condition: Heart Failure
Intervention: Device: Tele-monitoring and health coaching
Sponsors: Mayo Clinic; Preventice
Recruiting
Pursuit: Real World Use of the Eclipse System
NCT03940573
Condition: Fecal Incontinence
Intervention: Device: Eclipse Insert
Sponsor: Pelvalon, Inc.
Recruiting
Palbociclib in Real World Practice
NCT03280303
Conditions: Advanced Breast Cancer; Metastatic Breast Cancer
Intervention: Other: non-interventional
Sponsor: Pfizer
Recruiting
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )
NCT03518034
Conditions: Hypogonadism; Cardiovascular Diseases
Interventions: Drug: Testosterone; Drug: Placebo
Sponsors: AbbVie; Acerus Pharmaceuticals Corporation; Allergan Sales, LLC; Endo Pharmaceuticals; Upsher-Smith Laboratories
Recruiting
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223
Condition: Acute Coronary Syndrome
Interventions: Biological: Apolipoprotein A-I [human] (apoA-I); Other: Placebo
Sponsor: CSL Behring
Recruiting
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
NCT03315143
Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Diseases
Interventions: Drug: Sotagliflozin (SAR439954); Drug: Placebo
Sponsor: Sanofi
Recruiting
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency
NCT03037931
Conditions: Heart Failure; Iron-deficiency
Interventions: Drug: Ferric carboxymaltose; Drug: Placebos
Sponsors: American Regent, Inc.; Duke Clinical Research Institute
Recruiting
Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
NCT00443274
Condition: Breast Implant
Interventions: Other: NBIR Placeholder; Device: 410 Arm; Device: BIFs
Sponsor: Allergan
Recruiting
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853
Condition: Lung Cancer
Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
NCT03814187
Conditions: ASCVD; Elevated Cholesterol; Heterozygous Familial Hypercholesterolemia; Homozygous Familial Hypercholesterolemia
Intervention: Drug: Inclisiran Sodium
Sponsor: The Medicines Company
Recruiting
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT. NODE-302
NCT03635996
Condition: Paroxysmal Supraventricular Tachycardia
Intervention: Drug: Etripamil NS 70 mg
Sponsors: Milestone Pharmaceuticals Inc.; Medpace, Inc.
Recruiting
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Conditions: Overweight; Obesity
Interventions: Drug: Semaglutide; Drug: Placebo (semaglutide)
Sponsor: Novo Nordisk A/S
Recruiting
Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
NCT03464019
Condition: Paroxysmal Supraventricular Tachycardia
Interventions: Drug: Etripamil; Drug: Placebo; Device: Aptar Pharma Nasal Spray
Sponsors: Milestone Pharmaceuticals Inc.; Medpace, Inc.
Recruiting
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
NCT03439254
Conditions: Compensated Cirrhosis; Nonalcoholic Steatohepatitis
Interventions: Drug: Obeticholic acid (10 mg); Drug: Obeticholic acid (10 mg to 25 mg); Drug: Placebo
Sponsor: Intercept Pharmaceuticals
Recruiting
Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
NCT02993406
Conditions: Cardiovascular Diseases; Statin Adverse Reaction
Interventions: Drug: Bempedoic acid 180 mg tablet; Drug: Matching placebo tablet
Sponsors: Esperion Therapeutics; The Cleveland Clinic
Recruiting
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
NCT02793583
Conditions: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Interventions: Drug: TGR-1202 + Ublituximab; Drug: TGR-1202; Drug: TGR-1202 + Ublituximab + Bendamustine
Sponsor: TG Therapeutics, Inc.
Recruiting
The National Myelodysplastic Syndromes (MDS) Study
NCT02775383
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: Therapeutic
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
Recruiting
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
NCT02680574
Conditions: Anemia; Non-dialysis-dependent Chronic Kidney Disease
Interventions: Drug: vadadustat; Drug: darbepoetin alfa
Sponsor: Akebia Therapeutics
Recruiting
Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
NCT02648347
Conditions: Anemia; Non-dialysis-dependent Chronic Kidney Disease
Interventions: Drug: vadadustat; Drug: darbepoetin alfa
Sponsor: Akebia Therapeutics
Recruiting
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02630316
Conditions: Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema
Interventions: Drug: Inhaled Treprostinil; Drug: Placebo
Sponsor: United Therapeutics
Recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086
Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: photon beam radiation therapy; Radiation: proton beam radiation therapy; Drug: temozolomide; Other: laboratory biomarker analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
NCT02089217
Condition: Carotid Stenosis
Interventions: Procedure: Carotid endarterectomy (CEA); Device: Carotid Stenting (CAS); Other: Intensive Medical Management - no CEA; Other: Intensive Medical Management - no CAS
Sponsors: Thomas G. Brott, M.D.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting
Endoscopic Suturing (ES) Registry
NCT03776188
Condition: Surgery
Intervention:
Sponsors: American Gastroenterological Association; Apollo Endosurgery, Inc.
Recruiting
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
NCT03585270
Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: Clazosentan; Drug: Placebo
Sponsor: Idorsia Pharmaceuticals Ltd.
Recruiting
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350
Condition: Prostatic Neoplasms, Castration-Resistant
Interventions: Drug: Niraparib 200 mg; Drug: JNJ-63723283 240 mg; Drug: JNJ-63723283 480 mg; Drug: Abiraterone Acetate; Drug: Prednisone
Sponsor: Janssen Research & Development, LLC
Recruiting
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03882970
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Tirzepatide; Drug: Insulin Degludec
Sponsor: Eli Lilly and Company
Recruiting
Post-Approval Study of the TECNIS SYMFONY® Toric Lenses
NCT03791619
Conditions: Cataract; Corneal Astigmatism
Interventions: Device: Higher Cylinder Toric IOL; Device: Lower Cylinder Toric IOL
Sponsor: Johnson & Johnson Surgical Vision, Inc.
Recruiting
To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
NCT03777059
Condition: Episodic Migraine
Interventions: Drug: Atogepant 30 mg; Drug: Atogepant 60 mg; Drug: Placebo; Drug: Atogepant 10 mg
Sponsor: Allergan
Recruiting
A Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244
Condition: Prostatic Neoplasms
Interventions: Drug: Apalutamide; Drug: Androgen Deprivation Therapy (ADT); Drug: Placebo
Sponsor: Janssen Research & Development, LLC
Recruiting
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
NCT03561090
Condition: Gastroesophageal Reflux Disease (GERD)
Interventions: Drug: IW-3718; Drug: placebo
Sponsor: Ironwood Pharmaceuticals, Inc.
Recruiting
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
NCT03521934
Condition: Heart Failure-Type 2 Diabetes Mellitus
Interventions: Drug: Sotagliflozin (SAR439954); Drug: Placebo
Sponsor: Sanofi
Recruiting
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
NCT03510897
Condition: Cardiac Surgery
Interventions: Drug: QPI-1002; Drug: Placebo
Sponsor: Quark Pharmaceuticals
Recruiting
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
NCT03505021
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Levosimendan; Drug: Placebo for levosimendan
Sponsor: Orion Corporation, Orion Pharma
Recruiting
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD
NCT03496623
Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Interventions: Drug: Inhaled treprostinil solution; Drug: Placebo solution
Sponsor: United Therapeutics
Recruiting
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
NCT03417388
Condition: Coronary Artery Disease
Interventions: Drug: High dose potent statin; Drug: ACE-I (lisinopril) or ARB (losartan); Drug: Aspirin; Behavioral: Lifestyle Counseling; Behavioral: Quality of Life Questionnaires
Sponsors: University of Florida; United States Department of Defense
Recruiting
Hemodynamic-GUIDEd Management of Heart Failure
NCT03387813
Conditions: Heart Failure; Heart Failure, Systolic; Heart Failure, Diastolic; Heart Failure NYHA Class II; Heart Failure NYHA Class III; Heart Failure NYHA Class IV; Heart Failure，Congestive; Heart Failure With Reduced Ejection Fraction; Heart Failure With Normal Ejection Fraction; Heart Failure; With Decompensation
Intervention: Device: CardioMEMS™ HF System
Sponsor: Abbott Medical Devices
Recruiting
SPYRAL HTN-ON MED Study
NCT02439775
Conditions: Hypertension; Vascular Diseases; Cardiovascular Diseases
Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system; Procedure: Sham Procedure
Sponsor: Medtronic Vascular
Recruiting
Strategic Management to Optimize Response To Cardiac Resynchronization Therapy
NCT03089281
Condition: Heart Failure
Intervention: Device: CRT-D
Sponsor: Boston Scientific Corporation
Recruiting
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
NCT03057977
Condition: Heart Failure
Interventions: Drug: Empagliflozin; Drug: Placebo
Sponsors: Boehringer Ingelheim; Eli Lilly and Company
Recruiting
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
NCT03057951
Condition: Heart Failure
Interventions: Drug: Empagliflozin; Drug: Placebo
Sponsors: Boehringer Ingelheim; Eli Lilly and Company
Recruiting
Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT03043651
Condition: Pulmonary Hypertension Associated With HFpEF
Intervention: Drug: Oral Treprostinil
Sponsor: United Therapeutics
Recruiting
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
NCT03037580
Conditions: Pulmonary Hypertension; Heart Failure With a Preserved Ejection Fraction
Interventions: Drug: Oral treprostinil; Drug: Placebo
Sponsor: United Therapeutics
Recruiting
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
NCT02876835
Condition: Anaemia
Interventions: Drug: Daprodustat; Drug: Darbepoetin alfa; Drug: Placebo; Drug: Iron Therapy
Sponsor: GlaxoSmithKline
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
NCT02864953
Conditions: Brain Edema; Stroke, Acute
Interventions: Drug: BIIB093; Drug: Placebo
Sponsor: Biogen
Recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting
Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
NCT02403323
Condition: Crohn Disease
Intervention: Drug: etrolizumab
Sponsor: Hoffmann-La Roche
Recruiting
A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)
NCT02394028
Condition: Crohn Disease
Interventions: Drug: Etrolizumab; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting
Dimethyl Fumarate (DMF) Observational Study
NCT02047097
Condition: Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
Sponsor: Biogen
Recruiting
Connect® MDS/AML Disease Registry
NCT01688011
Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia
Intervention:
Sponsor: Celgene
Recruiting
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
NCT00887146
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group
Recruiting
Psoriasis Longitudinal Assessment and Registry (PSOLAR)
NCT00508547
Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: Ustekinumab; Biological: Biological therapies other than infliximab, ustekinumab and guselkumab; Drug: Conventional systemic agents; Biological: Infliximab; Biological: Guselkumab
Sponsor: Janssen Scientific Affairs, LLC
Recruiting
Longitudinal Early-onset Alzheimer's Disease Study Protocol
NCT03507257
Conditions: Early Onset Alzheimer Disease; Alzheimer Disease; Mild Cognitive Impairment
Interventions: Drug: Flortaucipir; Drug: Florbetaben
Sponsors: Liana Apostolova; Alzheimer's Therapeutic Research Institute; National Institute on Aging (NIA); Alzheimer's Association
Recruiting
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
NCT02730312
Conditions: Acute Myelogenous Leukemia; B-cell Acute Lymphoblastic Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Chronic Myeloid Leukemia, Blast Crisis
Intervention: Biological: XmAb14045
Sponsors: Xencor, Inc.; Chiltern International Inc.
Recruiting
Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
NCT03642210
Condition: Menorrhagia
Intervention: Combination Product: Levonorgestrel 52 mg intrauterine system
Sponsor: Medicines360
Recruiting
Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
NCT03951077
Condition: Polycystic Ovary Syndrome
Interventions: Drug: Elagolix; Drug: Placebo
Sponsor: AbbVie
Recruiting
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
NCT02273362
Conditions: Cirrhosis; Fibrosis; Hepatocellular Carcinoma; Phosphorylated Epidermal Growth Factor Receptor
Interventions: Drug: Erlotinib; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
NCT03605849
Conditions: Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder
Intervention: Drug: Centanafadine SR
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
NCT03605680
Conditions: Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder
Interventions: Drug: Centanafadine SR; Other: Placebo
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
NCT03572634
Conditions: Chronic Lymphocytic Leukemia; CLL; SLL; Small Lymphocytic Lymphoma
Interventions: Drug: TP-0903; Combination Product: TP-0903 and ibrutinib combination therapy
Sponsor: Tolero Pharmaceuticals, Inc.
Recruiting
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
NCT03206450
Conditions: Cancer Survivor; Osteosarcoma
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
NCT03002805
Condition: Sarcoma
Intervention: Drug: CBT-1®
Sponsor: CBA Research
Recruiting
Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study
NCT02188147
Condition: Syncope
Intervention: Device: Short Term Wearable Defibrillator
Sponsor: Zoll Medical Corporation
Recruiting
APL-101 Study for NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advance Solid Tumors
NCT03175224
Conditions: Solid Tumor; Advanced Cancer; Renal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; NSCLC; Lung Cancer
Intervention: Drug: APL-101 Oral Capsules (formerly CBT-101)
Sponsor: Apollomics Inc.
Recruiting
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Conditions: Advanced Cancer; Gastric Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer Metastatic; Colo-rectal Cancer; Solid Tumor; Solid Carcinoma; Solid Carcinoma of Stomach; Cancer of Stomach
Intervention: Drug: Minnelide™Capsules
Sponsors: Minneamrita Therapeutics LLC; Translational Drug Development
Recruiting
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
NCT03903822
Condition: Atopic Dermatitis
Interventions: Drug: PF-06700841; Drug: Vehicle (Placebo)
Sponsor: Pfizer
Recruiting
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
NCT03575871
Condition: Dermatitis, Atopic
Interventions: Drug: PF-04965842 100 mg; Drug: PF-04965842 200 mg; Drug: Placebo
Sponsor: Pfizer
Recruiting
OPsumit USers Registry
NCT02126943
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Opsumit (macitentan)
Sponsor: Actelion
Recruiting
Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility
NCT03641677
Condition: Lung Diseases
Interventions: Device: Centralized Lung Evaluation System; Procedure: Lung Transplant
Sponsor: Lung Bioengineering Inc.
Recruiting
Treatment With Intent to Generate Endovascular Reperfusion
NCT03474549
Condition: Ischemic Stroke
Intervention: Device: Tigertriever revascularization device
Sponsor: Rapid Medical
Recruiting
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
NCT03447990
Conditions: Dilated Cardiomyopathy; Heart Failure With Reduced Ejection Fraction
Intervention: Drug: MYK-491
Sponsor: MyoKardia, Inc.
Recruiting
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT03334409
Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v7; Unresectable Renal Cell Carcinoma
Interventions: Drug: Ascorbic Acid; Drug: Pazopanib Hydrochloride
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting
A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients
NCT03150420
Condition: Calciphylaxis
Interventions: Drug: Sodium Thiosulfate; Drug: Placebo-Normal Saline
Sponsor: Hope Pharmaceuticals
Recruiting
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
NCT03037164
Condition: Anemia
Interventions: Device: INTERCEPT Blood System for Red Blood Cells; Device: Conventional (Control)
Sponsor: Cerus Corporation
Recruiting
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
NCT02632721
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine; Drug: BI 836858
Sponsor: Boehringer Ingelheim
Recruiting
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
NCT02628405
Conditions: CD20 Positive; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma
Interventions: Drug: Carboplatin; Drug: Etoposide; Drug: Ifosfamide; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Biological: Rituximab
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting
MarginProbe® System U.S. Post-Approval Study
NCT02406599
Condition: Breast Cancer
Interventions: Device: Margin Probe; Other: Control: Additional inspection
Sponsor: Dune Medical Devices
Recruiting
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
NCT04000009
Condition: Adjunctive Treatment of Major Depressive Disorder
Intervention: Drug: Pimavanserin
Sponsor: ACADIA Pharmaceuticals Inc.
Recruiting
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
NCT03980730
Condition: Alzheimer Disease
Interventions: Drug: Azeliragon; Drug: Placebo
Sponsor: vTv Therapeutics
Recruiting
Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section
NCT03853694
Conditions: Elective Cesarean Section; Pain Management
Interventions: Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen; Drug: 150 mcg Duramorph + multi-modal pain regimen; Drug: Exparel TAP + multi-modal pain regimen
Sponsor: Pacira Pharmaceuticals, Inc
Recruiting
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
NCT02143726
Condition: Refractory Hurthle Cell Thyroid Cancer
Interventions: Drug: sorafenib; Drug: everolimus
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Novartis
Recruiting
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
NCT03745222
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Tislelizumab; Drug: Concurrent chemoradiotherapy (cCRT); Other: Placebo
Sponsors: Celgene; BeiGene
Recruiting
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
NCT03654313
Conditions: Atherosclerosis; Cardiovascular Disease
Interventions: Biological: MEDI6570; Biological: Placebo; Biological: Part B Placebo
Sponsor: MedImmune LLC
Recruiting
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
NCT03594110
Condition: Chronic Kidney Disease
Interventions: Drug: Empagliflozin; Drug: Matching placebo
Sponsors: Boehringer Ingelheim; Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead); Eli Lilly and Company
Recruiting
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
NCT03579771
Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Recruiting
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
NCT03489525
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate); Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
Sponsor: MedImmune LLC
Recruiting
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
NCT03487913
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: Lixivaptan
Sponsor: Palladio Biosciences
Recruiting
InterStim® Amplitude Study
NCT03335761
Condition: Urinary Urge Incontinence
Intervention: Device: InterStim Therapy
Sponsor: MedtronicNeuro
Recruiting
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03266692
Conditions: Multiple Myeloma; Multiple Myeloma in Relapse; Refractory Multiple Myeloma
Interventions: Biological: ACTR087; Biological: SEA-BCMA
Sponsors: Unum Therapeutics Inc.; Seattle Genetics, Inc.
Recruiting
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
NCT03230318
Conditions: Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Recruiting
A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy
NCT03054870
Condition: Lung Structure Determination
Interventions: Drug: Xe-133; Drug: Technegas
Sponsor: Cyclomedica Australia PTY Limited
Recruiting
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
NCT03030222
Condition: Heart Failure
Interventions: Drug: Empagliflozin 10Mg Tab; Drug: Placebo Oral Tablet
Sponsor: Saint Luke's Health System
Recruiting
Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
NCT02962895
Condition: Primary Sjogren's Syndrome
Interventions: Biological: VAY736; Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
NCT02952508
Conditions: Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle-Cell Lymphoma; Diffuse Large B Cell Lymphoma
Interventions: Drug: CLR 131 single dose; Drug: CLR 131 multiple dose
Sponsor: Cellectar Biosciences, Inc.
Recruiting
Eliminating Surgery After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT02945579
Conditions: Estrogen Receptor Negative; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma
Interventions: Radiation: External Beam Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Whole Breast Irradiation
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
NCT02924402
Conditions: B-cell Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Biological: XmAb13676
Sponsors: Xencor, Inc.; Chiltern International Inc.
Recruiting
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT02633059
Conditions: Loss of Chromosome 17p; Recurrent Plasma Cell Myeloma
Interventions: Drug: Dexamethasone; Drug: Idasanutlin; Drug: Ixazomib Citrate; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
NCT02372773
Condition: Familial Frontotemporal Dementia
Intervention:
Sponsors: Mayo Clinic; National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
NCT02357810
Conditions: Adult Liposarcoma; Metastatic Liposarcoma; Metastatic Osteosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Liposarcoma; Recurrent Osteosarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: Pazopanib Hydrochloride; Drug: Oral Topotecan Hydrochloride; Other: Laboratory Biomarker Analysis
Sponsors: Northwestern University; GlaxoSmithKline; National Cancer Institute (NCI)
Recruiting
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
NCT03955939
Condition: Metastatic Breast Cancer
Interventions: Drug: LY3295668 Erbumine; Drug: Endocrine therapy; Drug: Midazolam
Sponsor: Eli Lilly and Company
Recruiting
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
NCT03862040
Condition: Bacterial Pneumonia
Interventions: Drug: Cefiderocol; Drug: Standard of Care Antibiotic
Sponsor: Shionogi
Recruiting
Florida Pancreas Collaborative Next Generation Biobank
NCT03851133
Conditions: Pancreatic Cancer; Cancer Cachexia
Interventions: Other: Blood Sample Collection; Other: Tumor Sample collection; Other: Data Collection
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting
Triathlon® Partial Knee Replacement (PKR) Outcomes Study
NCT00966979
Condition: Arthroplasty, Replacement, Knee
Intervention: Device: Triathlon PKR
Sponsor: Stryker Orthopaedics
Recruiting
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
NCT03759379
Conditions: Amyloidosis, Hereditary; Transthyretin Amyloidosis
Interventions: Drug: Patisiran; Drug: Vutrisiran (ALN-TTRSC02)
Sponsor: Alnylam Pharmaceuticals
Recruiting
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
NCT03757949
Condition: Bladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Dietary Supplement: Nutritional Intervention; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
NCT03656536
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT03652064
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsor: Janssen Research & Development, LLC
Recruiting
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
NCT03649971
Condition: Adenomatous Polyposis Coli
Interventions: Drug: Guselkumab; Drug: Placebo
Sponsor: Janssen Research & Development, LLC
Recruiting
Compare Fallopian Tube Cells Collected by MAKO 7 With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
NCT03593681
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Ovarian Neoplasms; Ovary Cancer; Fallopian Tube Neoplasms; Fallopian Tube Adenocarcinoma; High Grade Serous Carcinoma; Peritoneal Carcinoma; Peritoneal Neoplasms; Adnexal Mass; Ovarian Diseases
Intervention: Device: Hysteroscopic cell sampling of the fallopian tube
Sponsors: nVision Medical; Boston Scientific Corporation
Recruiting
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817
Condition: Alzheimer's Disease
Intervention:
Sponsors: Washington University School of Medicine; National Institute on Aging (NIA)
Recruiting
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
NCT03561220
Condition: Prostate Cancer
Interventions: Radiation: Standard of Care IMRT (Photon); Radiation: Standard of Care Proton Therapy; Radiation: Proton Arm 1: Standard Proton Therapy; Radiation: Proton Arm 2: Hypofractionated Proton Therapy
Sponsors: University of Florida; Patient-Centered Outcomes Research Institute
Recruiting
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03539744
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Venetoclax
Sponsor: AbbVie
Recruiting
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Melphalan; Drug: Prednisone; Drug: Carfilzomib
Sponsor: Janssen Research & Development, LLC
Recruiting
A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC
NCT03295006
Condition: Hepatocellular Carcinoma
Intervention: Device: TheraSphere
Sponsor: BTG International Inc.
Recruiting
A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma
NCT03287908
Condition: Relapsed/Refractory Multiple Myeloma
Intervention: Drug: AMG 701
Sponsor: Amgen
Recruiting
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706
Condition: Non-Small Cell Lung Cancer
Interventions: Biological: Ipilimumab; Biological: Nivolumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Cisplatin
Sponsor: Bristol-Myers Squibb
Recruiting
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
NCT03194542
Conditions: Primary Myelofibrosis; Anemia
Intervention: Drug: Luspatercept
Sponsor: Celgene
Recruiting
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721
Condition: Pediatric Patients Treated With Radiation Therapy
Intervention: Other: No intervention
Sponsor: Massachusetts General Hospital
Recruiting
Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy
NCT03080883
Conditions: Cerebral Vein Thrombosis; Deep Vein Thrombosis; Malignant Neoplasm; Metastatic Malignant Neoplasm; Pulmonary Embolism; Splanchnic Vein Thrombosis
Intervention: Drug: Apixaban
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672
Conditions: ALK-Positive Large B-Cell Lymphoma; Atypical Burkitt/Burkitt-Like Lymphoma; Burkitt-Like Lymphoma With 11q Aberration; Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Mucocutaneous Ulcer; High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Human Herpesvirus 8-Positive Neoplastic Cells Present; Intravascular Large B-Cell Lymphoma; Large B-Cell Lymphoma With IRF4 Rearrangement; Plasmablastic Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System; Primary Effusion Lymphoma; Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Lymphomatoid Granulomatosis; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions: Biological: Nivolumab; Drug: Varlilumab
Sponsor: National Cancer Institute (NCI)
Recruiting
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT03001882
Condition: Non-Small Cell Lung Cancer
Interventions: Biological: Nivolumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Yale University
Recruiting
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
NCT02964507
Condition: Neoplasms
Interventions: Drug: GSK525762; Drug: Placebo; Drug: Fulvestrant
Sponsor: GlaxoSmithKline
Recruiting
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
NCT02898207
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Triple-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm
Interventions: Drug: Olaparib; Drug: Onalespib
Sponsor: National Cancer Institute (NCI)
Recruiting
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
NCT02756845
Condition: Advanced Non CNS Tumors
Intervention: Drug: Talimogene Laherparepvec
Sponsor: Amgen
Recruiting
Study of Iomab-B Prior to Hematopoietic Cell Transplant vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
NCT02665065
Conditions: Acute Myeloid Leukemia; Leukemia, Acute Myeloid; Myeloid Leukemia, Acute; Leukemia, Myeloid, Acute; Acute Myelogenous Leukemia; Leukemia, Acute Myelogenous; Myelogenous Leukemia, Acute; AML; Bone Marrow Transplant
Interventions: Drug: Iomab-B; Drug: Conventional Care; Procedure: HCT
Sponsor: Actinium Pharmaceuticals
Recruiting
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
NCT02601950
Conditions: Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of Ovary; Renal Medullary Carcinoma; Epithelioid Sarcoma; Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval); Any Solid Tumor With an EZH2 GOF Mutation
Intervention: Drug: Tazemetostat
Sponsor: Epizyme, Inc.
Recruiting
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
NCT02549092
Condition: Advanced Parkinson's Disease
Intervention: Drug: ABT-SLV187
Sponsor: AbbVie
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis
NCT03945279
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: BIIB100; Drug: Placebo
Sponsor: Biogen
Recruiting
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
NCT02475213
Conditions: Melanoma; Head and Neck Cancer; Non Small Cell Lung Cancer; Urethelial Carcinoma
Interventions: Biological: Enoblituzumab; Biological: Pembrolizumab; Biological: MGA012
Sponsor: MacroGenics
Recruiting
A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema
NCT03866473
Condition: Diabetic Macular Edema
Interventions: Device: Retilux; Device: Sham Light Device
Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; PhotoOptx LLC
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now